Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (March 2019)
24 slides from Aurobindo Pharma's investor presentation, March 2019
Slide 1: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Investor Presentation - March 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 3: Aurobindo Pharma – Overview
Aurobindo Pharma – Overview 10th Largest generic 2nd Largest listed 3rd Largest volume Amongst Top 10 Gx 32 years company by sales Indian Pharmaceutical supplier in the US** companies in 4 out in existence globally# company by revenues* of Top 5 Europe Countries@ $ 2.6 Bn 27 Manufacturing 155+ >26 B
Slide 4: The Journey So Far…
The Journey So Far… 2014 - 16 Acquired Western European commercial operations from Actavis Acquired Natrol Established OTC presence Entered into Biosimilars and Vaccines Filed first peptide DMF 2006-08 2017-19 Acquired UK based Milpharm Acquired Generis in Portugal and Apotex Inc’s A
Slide 5: Emerged into a leading global generic player
Emerged into a leading global generic player Revenue ($ Mn) EBITDA ($ Mn) & Margin Net Profit ($ Mn) Geographical Revenue Mix 23% 2,562 International Domestic 376 588 10 37 90 63 378 14% 37 53 2008 2018 2008 2018 2008 2018 2008 2018 Business Mix Employee Base ANDAs – Filing Status DMFs – Filing Stat
Slide 6: Core Strengths
Core Strengths • Among Top 3 in >65% of commercial portfolio in US(1) in terms of prescriptions • Large US portfolio(2) - 519 ANDAs filed; 369 with final approval, 28 Tentative approval(3), and 122 under review Scale & Diversity • Extensive product portfolio & pipeline across the globe • Experienced
Slide 7: US Business Highlights
US Business Highlights Revenue ($ Mn) Revenue Mix 1,156 Injectables Dietary Orals 1,019 930 939 7% Supplements 70% 792 11% Share of Non- Orals significantly OTC improved 3% Injectables Orals 16% 93% FY15 FY16 FY17 FY18 9MFY19 FY14 9MFY19 Cumulative ANDA Filings and Approvals Filing Mix 304 65 519 In
Slide 8: US Business – Segment Wise Highlights
US Business – Segment Wise Highlights Orals Injectables • 70% of overall US business in 9MFY19 • 16% of overall US business in 9MFY19 • Volume share increased to 5.2% (MAT Dec 2018) from • Volumes increased ~29%* (MAT Dec 18 vs. MAT Dec 4.3% (MAT Dec 2017)* 17) • Filed 29 ANDAs and launched 29 produ
Slide 9: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Portfolio mix is complemented with the introduction of high-value products ANDAs Addressable Market in US$ Bn 16.1 24.5 24.2 161 6.0* 91 81 3.7 0.7 9.0 4.6 1.4 0.7 42 0.4 0.5 0.3 30 21 30 19 17 11 12 2 2 Anti Diabetic ARV CNS Controlled CVS
Slide 10: Sandoz’s Dermatology and Oral Solids Businesses – Acquisition overview
Sandoz’s Dermatology and Oral Solids Businesses – Acquisition* overview Aurobindo Pharma USA Inc. entered into a definitive agreement with Sandoz Inc., USA to acquire its dermatology and oral solids businesses Acquired portfolio with c.70% revenue contribution by oral solids and c.30% by dermato
Slide 11: Post-Acquisition: 2nd Largest Generic Player in the US
Aurobindo would become the 2nd Largest Generic Player in the US Post Sandoz’s businesses acquisition Market Share in the US by Number of Prescriptions Dispensed 2nd 4th 14.3% 8.6% 3.1% 6.4% 5.7% 5.5% 4.1% 3.3% 3.0% 3.0% 2.8% 2.8% 2.7% 5.5% 3.1% 1.0% Post-Acquisition 10 1) Source: IQVIA MAT Jul 2018
Slide 12: Acquisition of branded oncology injectables from Spectrum Pharmaceuticals
Acquisition of branded oncology injectables from Spectrum Pharmaceuticals - Overview Acrotech Biopharma, a step-down subsidiary of Aurobindo Pharma Limited has acquired portfolio of seven marketed oncology injectable products from Spectrum Pharmaceuticals Acquisition brings-in an experienced bra
Slide 13: EU Business Highlights
EU Business Highlights Strong foothold in Europe Revenue (€ Mn) • Operations in 11 countries with full fledged Pharmacy, Hospital 13% CAGR in FY15 – FY18 577 and Tender sales infrastructure with commercialized 450+ INNs 434 446 450 • Ranks amongst the Top 10@ Generic companies in four out of 413 T
Slide 14: Aurobindo’s Footprint in Europe Post Apotex Acquisition
Aurobindo’s Footprint in Europe Post Apotex Acquisition France Spain: Existing + Acquired ► Ranks #1 by volume for hospital segment; 5th ► 13th largest generic company position in the retail market ► Number of products total marketed: 182 ► Number of products currently marketed: 268 Germany Netherla
Slide 15: Growth Markets & ARV Business – Highlights
Growth Markets & ARV Business – Highlights Growth Markets Business Revenue ($ Mn) 14% CAGR in FY15-FY18 139 Key markets includes Canada, Brazil and South Africa 130 113 Targeted to build branded generics presence in select markets 93 99 In the process of strengthening operations and portfolio
Slide 16: API Business - Highlights
API Business - Highlights API capacity is strategic in-terms of vertical integration and supply reliability Additional investments are made for capacity creation and capability building Customers include innovator and large generic companies API business continue to focus on complex products
Slide 17: Consolidated Financial Performance – Q3FY19
Consolidated Financial Performance – Q3FY19 Q3 Q3 % Q2 % Value $ Mn FY19 FY18 Chg FY19 Chg Formulations 605.1 555.9 8.9 562.6 7.6 API 128.3 119.2 7.6 116.7 9.9 Formulations % of sales 82.5% 82.3% 82.8% Revenue from Operations 733.4 675.1 8.6 679.3 8.0 Gross Profit 400.8 392.1 2.2 387.2 3.5 Overheads
Slide 18: Financial Performance
Financial Performance Revenue from Operations ($ Mn) EBITDA & PAT Margin (%) EPS (INR/Share) 2,562 23.0 39.3 41.4 22.8 22.8 2,137 2,253 21.2 34.7 2,048 19.9 19.8 19.7 20.3 1,986 30.4 18.4 27.0 16.7 15.3 14.7 14.5 13.0 12.5 FY15 FY16 FY17 FY18 9MFY19 FY15 FY16 FY17 FY18 9MFY19 EBITDA Margin Adj PBT M
Slide 19: Debt Profile
Debt Profile Fx Loan US$ Mn $ Mn Mar-16 Mar-17 Mar-18 Sep-18 Dec-18 748 481 731 758 771 Fx Loan restated 748 481 731 758 771 Rupee Loan 7 38 1 39 42 Sales Tax Deferment 6 0 0 0 0 Gross Debt 762 519 732 797 813 Cash Balance 122 80 194 245 254 Net Debt 640 439 538 551 559 Finance Cost 1.8% 1.5% 2.0% 2
Slide 20: Focus on Building a Diverse and Robust Specialty Products Portfolio
Focus on Building a Diverse and Robust Specialty Products Portfolio Oncology & Hormones Peptides Depot Injections Controlled Substances Topicals Transdermal Patches Inhalers Nasals Biosimilars Vaccines 505(b)(2) products Consumer Healthcare 19
Slide 21: Specialty Products Portfolio (1/2)
Focus on Building a Diverse and Robust Specialty Products Portfolio (1/2) Oncology & Topicals Nasals Peptides Depot Injection Hormones Products under 79 22 5 14 4 development Addressable Market Size $45 Bn $5 Bn $0.5 Bn $12.2 Bn $3.6 Bn Filing Status ANDAs*: Oncology- To start from ANDAs*: 2 ANDAs*:
Slide 22: Specialty Products Portfolio (2/2)
Focus on Building a Diverse and Robust Specialty Products Portfolio (2/2) Transdermal Inhalers Biologics Vaccines Patches Products under 8 9 6* 1 development Addressable Market Size $3.2 Bn $9.5 Bn $35 Bn $6.2 Bn Filing to start from FY20 FY20 FY21 FY21 Filing Target To file all products To file all
Slide 23: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India >1,500 scientists and analysts R&D Spend – $ Mn (as % of revenue) Focused on difficult to develop APIs, peptides, etc. 5.0%* 5.6%* Develop modern process technologies like enzyme chemistry 4.3%* 103 4.0%* 92 Dosage
Slide 24: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of
Aurobindo Pharma — Investor Presentation (March 2019) on 6ix